Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OKYO PharmaOKYO +4.14%24 PB Ratio is 6.43 as of Jul. 22, 2026. GuruFocus rates OKYO with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, OKYO Pharma ranks worse than 81366.88% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-22), OKYO Pharma's share price is $1.51. OKYO Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.24. Hence, OKYO Pharma's PB Ratio of today is 6.43.
The historical rank and industry rank for OKYO Pharma's PB Ratio or its related term are showing as below:
OKYO'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6.29
Current: 6.29
During the past 13 years, OKYO Pharma's highest PB Ratio was 6.29. The lowest was 0.00. And the median was 0.00.
OKYO's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.82
vs OKYO: 6.29
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of OKYO Pharma was 418.00% per year. The lowest was -79.50% per year. And the median was -30.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
OKYO Pharma PB Ratio Related Terms
OKYO Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for OKYO Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OKYO Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OKYO Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OKYO Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where OKYO Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
OKYO Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
OKYO Pharma (OKYO) has a PB Ratio of 6.43 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OKYO Pharma and its competitors. According to the industry distribution chart, OKYO Pharma ranks #999999 out of 1229 companies in the Biotechnology industry.
Is OKYO Pharma's PB Ratio too high?
OKYO Pharma's current PB Ratio is 6.43. The Biotechnology industry median PB Ratio is 2.82. OKYO Pharma's value of 6.43 is 128% above this industry median. Based on the distribution chart, OKYO Pharma ranks #999999 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OKYO Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's PB Ratio compare to ENTX and HRTX?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #999999 out of 1229 companies for PB Ratio. This places OKYO Pharma in the lower half of its industry. The industry median PB Ratio is 2.82. OKYO Pharma's value of 6.43 is 128% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OKYO Pharma's current PB Ratio of 6.43 is 128% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OKYO Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OKYO Pharma's current PB Ratio is 6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (OKYO) has a current PB Ratio of 6.43. The current PB Ratio is 6.43 and 128% above the Biotechnology industry median of 2.82. OKYO Pharma's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For OKYO Pharma (OKYO), the current PB Ratio is 6.43 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
24GF Score
Get the complete analysis for OKYO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OKYO has been successfully added to your 
